These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22287728)

  • 1. Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC).
    Stoehlmacher-Williams J; Obermann L; Ehninger G; Goekkurt E
    Anticancer Res; 2012 Feb; 32(2):421-5. PubMed ID: 22287728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
    Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
    Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.
    Lee JM; Yang SY; Yang PW; Shun CT; Wu MT; Hsu CH; Lin CC; Cheng JC; Wang YH; Chuang TH; Chen JS; Hsu HH; Huang PM; Kuo SW; Lee YC
    Ann Surg Oncol; 2011 Jul; 18(7):2066-73. PubMed ID: 21298351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
    Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
    J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
    Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
    J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
    Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
    Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients.
    Bandrés E; Barricarte R; Cantero C; Honorato B; Malumbres R; Zárate R; Alcalde J; García-Foncillas J
    Oral Oncol; 2007 Aug; 43(7):713-9. PubMed ID: 17112774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
    Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
    Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
    Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines.
    Krohn V; Wiegand S; Werner JA; Mandic R
    Anticancer Res; 2011 Jan; 31(1):59-65. PubMed ID: 21273581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab.
    Zhang W; Gordon M; Press OA; Rhodes K; Vallböhmer D; Yang DY; Park D; Fazzone W; Schultheis A; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    Pharmacogenet Genomics; 2006 Jul; 16(7):475-83. PubMed ID: 16788380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: a retrospective analysis.
    Rangaraju RR; Sharma JB; Dewan AK; Anand AK; Sheh R; Jena A; Chaturvedi AK
    Indian J Cancer; 2012; 49(1):1-5. PubMed ID: 22842160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation.
    Zhang W; Park DJ; Lu B; Yang DY; Gordon M; Groshen S; Yun J; Press OA; Vallböhmer D; Rhodes K; Lenz HJ
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):600-5. PubMed ID: 15701846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
    J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.
    Hama T; Yuza Y; Saito Y; O-uchi J; Kondo S; Okabe M; Yamada H; Kato T; Moriyama H; Kurihara S; Urashima M
    Oncologist; 2009 Sep; 14(9):900-8. PubMed ID: 19726454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
    Chung CH; Ely K; McGavran L; Varella-Garcia M; Parker J; Parker N; Jarrett C; Carter J; Murphy BA; Netterville J; Burkey BB; Sinard R; Cmelak A; Levy S; Yarbrough WG; Slebos RJ; Hirsch FR
    J Clin Oncol; 2006 Sep; 24(25):4170-6. PubMed ID: 16943533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.
    Bontognali S; Pless M; Brutsche MH; Fischer C; Rochlitz C; Buess M
    Onkologie; 2013; 36(4):161-6. PubMed ID: 23548963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased activity of superoxide dismutase in advanced stages of head and neck squamous cell carcinoma with locoregional metastases.
    Salzman R; Kanková K; Pácal L; Tomandl J; Horáková Z; Kostrica R
    Neoplasma; 2007; 54(4):321-5. PubMed ID: 17822322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.